Differentially expressed circular RNAs in peripheral blood mononuclear cells of PD patients

Stylianos Ravanidis; Anastasia Bougea; Dimitra Karampatsi; Nikolaos Papagiannakis; Matina Maniati; Leonidas Stefanis; Epaminondas Doxakis

doi:10.1101/2020.11.14.20231779

ABSTRACT

Background New noninvasive and affordable molecular approaches that will complement current practices and increase the accuracy of PD diagnosis are urgently needed. CircRNAs are highly stable non-coding RNAs that accumulate with aging in neurons and are increasingly shown to regulate all aspects of neuronal development and function.

Objectives The aims of the present study were to identify differentially expressed circRNAs in PBMCs of idiopathic PD patients and explore the competing endogenous RNA networks affected.

Methods Eighty-seven circRNAs were initially selected based on relatively high gene expression in the human brain. Over half of these were readily detectable in PBMCs using RT-qPCR. Comparative expression analysis was then performed in PBMCs from sixty controls and sixty idiopathic subjects with PD.

Results Six circRNAs derived from MAPK9, HOMER1, SLAIN1, DOP1B, REPS1, and PSEN1 transcripts were significantly downregulated in PD patients. The classifier that best distinguished PD consisted of four circRNAs with an AUC of 0.84. CLIP-Seq data revealed that the RNA binding proteins bound by most of the deregulated circRNAs include the neurodegeneration-associated FUS, TDP43, FMR1 and ATXN2. MicroRNAs predicted to be sequestered by most deregulated circRNAs had the GOslim categories ‘Protein modification’, ‘Transcription factor activity’ and ‘Cytoskeletal protein binding’ mostly enriched.

Conclusions This is the first study that identifies circRNAs deregulated in the peripheral blood of PD patients. They may serve as diagnostic biomarkers and since they are highly expressed in the brain and are derived from genes with essential brain functions, they may also hint on the PD pathways affected.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

This research was financed by Greece and European Union (European Social Fund‐ESF) through the Operational Program, Human Resources, Development, Education and Lifelong Learning 2014‐2020 in the context of the project Development of diagnostic biomarker tests for Parkinson's disease (MIS 5049385). It was also co-financed by the action Precision medicine Hellenic network in genetic neurodegenerative diseases (2018ΣΕ01300001) of the Hellenic public investments program of GSRT and the Michael J. Fox Foundation for Parkinson's Research (Grant ID 13353). The authors have received no payments or services from a third party for any aspect of the submitted work.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The Eginition hospital and BRFAA ethics committees approved the study and all participants provided written consent.

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes